Oncotelic Therapeutics

Oncotelic Therapeutics EBIT Margin

The EBIT Margin (Operating Margin) of Oncotelic Therapeutics (OTLC) as of Nov 5, 2026 is -806.96 %. In the previous year, EBIT Margin (Operating Margin) was -435.69 % — a change of 85.21% (lower).

EBIT Margin

-806.96 %

YoY

85.21%

Last updated:

EBIT Margin (Operating Margin) of Oncotelic Therapeutics is 2023 -806.96 % . EBIT Margin (Operating Margin) of Oncotelic Therapeutics was 2022 -435.69 % . It decreases by 85.21% lower compared to the previous year.

For Oncotelic Therapeutics, the operating (EBIT) margin of -807.0% is up versus -5,031.3% a few years ago.

The Oncotelic Therapeutics EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2007
-2,227.00 USD
Jan 1, 2008
-2,594.00 USD
Jan 1, 2012
-50.31 USD
Jan 1, 2013
-82.80 USD
Jan 1, 2019
-1,264.72 USD
Jan 1, 2020
-435.69 USD
Jan 1, 2023
-806.96 USD
The Oncotelic Therapeutics EBIT Margin history
YEAREBIT MarginYoY
-806.96 %+85.21%
-435.69 %-65.55%
-1,264.72 %+1,427.45%
-82.80 %+64.57%
-50.31 %-98.06%
-2,594.00 %+16.48%
-2,227.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oncotelic Therapeutics Stock analysis

What does Oncotelic Therapeutics do? Oncotelic Therapeutics, Inc. develops anti-vascular therapeutics for cancer and sight-threatening eye diseases, focusing on orphan oncology indications. The company's pipeline includes OT-101, an antisense drug targeting TGF-2 for solid tumors, brain cancer in adults, and DIPG in children, as well as for treating SARS and COVID-19 viruses. CA4P, a vascular disrupting agent combined with Ipilimumab, targets melanoma in adults and pediatric cases. Oxi4503, another VDA, focuses on childhood leukemia. The company generates revenue through drug development and potential future sales of these therapeutics, targeting patients with rare cancers and viral infections. Oncotelic's products are developed for specific medical segments: OT-101 serves adult brain cancer patients and pediatric DIPG cases, while CA4P addresses melanoma in both adult and pediatric populations. Oxi4503 targets childhood leukemia, a liquid tumor condition. The company's therapeutic focus on rare and specialized conditions positions it to work with healthcare providers and potentially pharmaceutical partners for clinical trials and eventual market entry. The firm's development of antisense and small molecule injectable drugs for cancer treatment aligns with its strategy to address unmet medical needs in orphan indications. By targeting TGF-2, CA4P, and Oxi4503, Oncotelic aims to provide innovative treatments for conditions with limited therapeutic options, potentially leading to partnerships or licensing agreements for drug commercialization. Oncotelic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncotelic Therapeutics stock

EBIT Margin (Operating Margin) of Oncotelic Therapeutics is -806.96 % in 2023.

EBIT Margin (Operating Margin) of Oncotelic Therapeutics changed from -435.69 % to -806.96 %, representing a 85.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Oncotelic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Oncotelic Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Oncotelic Therapeutics

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Oncotelic Therapeutics